PVD News

VASCULAR NEWS

At this year’s International Symposium on Endovascular Therapy (ISET 2022; 16–19 January, Hollywood, USA), experts presented an array of late-breaking trial results on topics ranging from venous stenting to abdominal aortic aneurysm (AAA) sac sealing. Waseem Wahood (Dr Kiran C Patel College of Allopathic Medicine, Davie, USA) gave a US national perspective on disparities in the treatment of peripheral arterial disease (PAD) and chronic limb-threatening ischaemia (CLTI).

MEDICAL XPRESS

There is an increased risk for venous thromboembolism (VTE) and peripheral vascular disease (PVD) among patients with psoriatic disease, according to a review published online Dec. 1 in JAMA Dermatology.

DOCWIRE NEWS

Peripheral arterial disease (PAD) patients face a high risk of limb amputation, according to the European Journal of Vascular and Endovascular Surgery.

The ultimate aim of this study was to assess the link between long term risk of hospitalization for heart failure (HHF) and lower extremity minor and major amputation (LEA) in patients initiating sodium glucose cotransporter 2 inhibitors (SGLT2i) suffering from type 2 diabetes and PAD.

CATHETERIZATION & CARDIOVASCULAR INTERVENTIONS

Abstract

Background: Endarterectomy is considered the gold standard therapy for common femoral artery (CFA) steno-occlusive lesions, but a significant risk of perioperative mortality and complications has been reported.

Objective: Aim of this study is to evaluate the efficacy at a long-term follow-up of patients with CFA steno-occlusive lesions treated with directional atherectomy and drug coated balloon (DCB).

VASCULAR NEWS

Royal Philips today announced the results of a new large-scale real-world analysis of Centers for Medicare & Medicaid Services (CMS) data on the health outcomes of peripheral vascular interventions guided by intravascular ultrasound (IVUS).

VASA

Summary: Patients with peripheral arterial disease (PAD) are at very high risk of cardiovascular events, but risk factor management is usually suboptimal. This Joint Task Force from the European Atherosclerosis Society and the European Society of Vascular Medicine has updated evidence on the management on dyslipidaemia and thrombotic factors in patients with PAD. Guidelines recommend a low-density lipoprotein cholesterol (LDLC) goal of more than 50% reduction from baseline and <1.4 mmol/L (<55 mg/dL) in PAD patients. As demonstrated by randomized controlled trials, lowering LDL-C not only...

JOURNAL OF THE AMERICAN HEART ASSOCIATION

Background: Ankle‐brachial index (ABI) is used to identify lower‐extremity peripheral artery disease (PAD). However, its association with severe ischemic leg outcomes (eg, amputation) has not been investigated in the general population.

MEDICAL DIALOGUES

Patients with peripheral artery disease (PAD) undergoing lower extremity revascularization (LER) benefit from low-dose rivaroxaban and aspirin therapy, suggests a study published in the Circulation. Patients with peripheral artery disease (PAD) are at heightened risk of acute limb ischemia (ALI), a thrombotic event associated with amputation, disability, and mortality. Prior lower extremity revascularization (LER) is associated with increased ALI risk in chronic peripheral artery disease (PAD).

BIZ NEW ORLEANS

Cardiovascular Institute of the South founder Craig Walker said he is the first physician in the U.S. to use the Philips Laser System Nexcimer to reopen blockages in arteries. The first case took place on Oct. 28 at the CIS Ambulatory Surgery Center in Gray, Louisiana to treat peripheral artery disease in the legs.

DOCWIRE NEWS

Introduction: Guideline-directed medical therapy (GDMT) is imperative to improve cardiovascular and limb outcomes for patients with critical limb ischemia (CLI), especially amongst those at highest risk for poor outcomes, including those with comorbid chronic kidney disease (CKD). Our objective was to examine GDMT prescription rates and their variation across individual sites for patients with CLI undergoing peripheral vascular interventions (PVIs), by their comorbid CKD status.